pharmaphorum August 9, 2022
Healthcare technology firm Koneksa will carry out a study to evaluate whether digital biomarkers can be used to track the progression of Parkinson’s disease – thanks to a grant from the Michael J Fox Foundation.
Quantitative tools for measuring progression are lacking in Parkinson’s disease and other neurological disorders, with clinicians relying on subjective measures that make it harder to monitor patients, as well as develop new therapies to help them.
Koneksa is planning to apply artificial intelligence algorithms retrospectively to a database of digital data on measures like activity, gait and sleep collected from Parkinson’s patients who used the Verily study watch, a wearable device used to capture physiological and environmental data.
There’s no doubt that it is a...
Today's Sponsors
Today's Sponsor